Across TCGA pan-cancer cohorts, EN2 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated EN2 data layer compared with 23 for mass-spec protein.
The strongest signal is observed in small cell lung cancer (SCLC), where higher EN2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EN2 expression acts as an unfavorable survival marker.
SCLC are the cancer types where EN2 Mutation most reproducibly stratifies survival.